Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 17/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4859626 | 0.85 | TGFBR1 (0.59) | PIK3CATGFBR1MAPK14 | |
| SCHEMBL4864998 | 0.84 | TGFBR1 (0.47) | PIK3CDPIK3CATGFBR1MAPK14 | |
| SCHEMBL29796648 | 0.84 | KDM4E (0.43) | TGFBR1MAPK14 | |
| SCHEMBL23389738 | 0.84 | KDM4E (0.43) | TGFBR1MAPK14 | |
| SCHEMBL23408260 | 0.84 | TGFBR1 (0.43) | TGFBR1MAPK14 | |
| SCHEMBL4878226 | 0.83 | TGFBR1 (0.59) | TGFBR1MAPK14 | |
| SCHEMBL4868724 | 0.82 | TGFBR1 (0.42) | PIK3CDPIK3CATGFBR1MAPK14EGFR | |
| SCHEMBL25084975 | 0.81 | TGFBR1 (0.42) | TGFBR1MAPK14 | |
| SCHEMBL4859601 | 0.81 | MAPK14 (0.44) | PIK3CDPIK3CATGFBR1MAPK14EGFR | |
| SCHEMBL25084720 | 0.79 | CHRNB2 (0.47) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275235-A1 | NOVEL FUSED HETEROAROMATIC COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-7417041-B2 | Imidazopyrimidines as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-20040176390-A1 | Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275235-A1 | NOVEL FUSED HETEROAROMATIC COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | TGFBR1, SMAD3, SMAD2 | PIK3CD 734/4885PIK3CA 823/4885TGFBR1 1/4885 |
| US-20040176390-A1 | Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors | SMAD3, TGFBR1, SMAD2 | PIK3CD 641/4885PIK3CA 812/4885TGFBR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.